#USA #New York #Class Action #Pomerantz LLP #Rocket Pharmaceuticals

Investor Alert: Class Action Lawsuit Filed Against Rocket Pharmaceuticals

On July 12, 2025, the Pomerantz Law Firm, a reputable entity in the realm of class action litigation, officially announced the filing of a class action lawsuit against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). This lawsuit comes in response to significant losses suffered by investors of Rocket Pharmaceuticals, raising concerns about possible securities fraud and the company’s business practices.

Key Details of the Lawsuit

The class action is filed on behalf of investors who might have been misled regarding Rocket Pharmaceuticals' operations and the safety of their investigational therapies. Specifically, the lawsuit arises after a recent incident involving RP-A501, a gene therapy being developed for treating Danon disease. Reports surfaced that a patient involved in the Phase 2 pivotal trial experienced an unexpected serious adverse event (SAE) related to capillary leak syndrome, which led to a tragic loss of life.

On May 27, 2025, after the adverse event news broke, Rocket Pharmaceuticals' stock plummeted by over 62%, closing at $2.33 per share – a decline that has raised alarms among investors and prompted this collective legal action.

Instructions for Affected Investors

Investors who have suffered losses due to their investment in Rocket Pharmaceuticals during the designated Class Period are urged to contact Pomerantz LLP. Danielle Peyton, a representative of the firm, can be reached via email at [email protected] or by phone at 646-581-9980, toll-free at 888.4-POMLAW, ext. 7980. Those interested in becoming Lead Plaintiffs are advised to express their intent to the court before the deadline of August 11, 2025. To further assist potential class members, Pomerantz provides access to relevant legal documents and a copy of the Complaint on their website.

Background on Rocket Pharmaceuticals

Rocket Pharmaceuticals specializes in developing gene therapies for rare diseases. As a pioneering entity in this innovative field, their mission aims to provide hope to patients afflicted with serious genetic conditions. However, the recent challenges raised through this lawsuit highlight the critical need for transparency and accountability in their clinical trials.

The concerning results from the RP-A501 trial led pivotal media outlets to cover the unfortunate event, with investors expressing betrayal and a lack of confidence in the company's management. This sentiment is rippling through the market, marking a pivotal shift in how stakeholders view Rocket Pharmaceuticals.

Pomerantz LLP: A History of Advocacy

Pomerantz LLP, recognized for its extensive experience and success in securities class litigation, boasts a long-standing commitment to defending the rights of investors. Established over 85 years ago, the firm has consistently fought against securities fraud and corporate misconduct, recovering significant damages for its clients.

As the legal proceedings unfold, investors are encouraged to stay informed and engaged. Pomerantz is committed to keeping class action participants apprised of developments, advocating for those affected by Rocket Pharmaceuticals’ alleged missteps in its clinical trial process.

Conclusion

The class action lawsuit against Rocket Pharmaceuticals represents an important step for investors seeking justice. Pomerantz LLP’s dedication to this cause reinforces the firm’s legacy of supporting the rights of investors and demanding accountability from corporations. With significant deadlines approaching, affected investors must act promptly to ensure their voice is heard in this notable case. To stay updated, further information can be accessed via www.pomerantzlaw.com.

For media inquiries or further legal assistance, Pomerantz LLP remains available to address concerns and provide support for those affected by the alleged infractions by Rocket Pharmaceuticals.